IP Library Granted Patent US 10,201,548
Granted Patent B2
US 10,201,548 · App. 12/399,729 · Granted Feb 12, 2019

Methods for treating ocular inflammatory diseases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,201,548
App. No.
12/399,729
Granted
Feb 12, 2019
Kind
B2
Abstract

A method of treating blepharitis includes administering to the affected eye of a subject an effective amount of an active ingredient in an ophthalmically acceptable vehicle for a sufficient period of time to treat blepharitis. The active ingredient consists essentially of a glucocorticoid in an ophthalmically acceptable vehicle that includes an aqueous polymer suspension that when mixed with tear fluid provides a sustained release of said active ingredient. The aqueous polymer suspension includes a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and has a viscosity in a range from about 1,000 to about 30,000 centipoises. A kit includes: (a) a composition comprising about 0.1% by weight dexamethasone in this ophthalmically acceptable vehicle and (b) instructions for using the composition of (a) for the treatment of blepharitis.

Claims (5)

1. A method of treating blepharitis having as its pathophysiological origin bacteria, the method comprising administering twice daily to the affected eye of a subject who has said blepharitis, for 14 days or more, a composition comprising an active ingredient consisting of about 0.1% by weight dexamethasone in an ophthalmically acceptable vehicle,

wherein the ophthalmically acceptable vehicle comprises an aqueous polymer suspension comprising a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and an initial viscosity in a range from about 1,000 to about 30,000 centipoises, and which gels on contact with tear fluid,

wherein the method does not comprise administration of an antibiotic.

2. The method of claim 1 , wherein the carboxyl-containing polymer is polycarbophil.

3. The method of claim 2 , wherein the ophthalmically acceptable vehicle comprises 0.9% by weight of polycarbophil, 0.2% by weight of Polaxamer 407, an osmolality adjusting agent, a buffer in an amount sufficient to adjust a pH of the ophthalmically acceptable vehicle to be in a range from 3 to 6.5, and a preservative.

Assignments (10)
MERGER Recorded Mar 28, 2023
From: SUN PHARMA GLOBAL FZE
To: SUN PHARMACEUTICAL INDUSTRIES LIMITED
Reel/Frame 063126/0715 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 9, 2018
From: INSITE VISION INCORPORATED
To: SUN PHARMA GLOBAL FZE
Reel/Frame 044883/0912 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2016
From: INSITE VISION INCORPORATED
To: SUN PHARMA GLOBAL FZE
Reel/Frame 038456/0649 →
RELEASE OF SECURITY INTEREST Recorded Nov 18, 2015
From: U.S. BANK NATIONAL ASSOCIATION
To: INSITE VISION INCORPORATED
Reel/Frame 037065/0458 →
RELEASE OF SECURITY INTEREST Recorded Nov 17, 2015
From: RANBAXY, INC.
To: INSITE VISION INCORPORATED
Reel/Frame 037064/0929 →
SECURITY INTEREST Recorded Sep 17, 2015
From: INSITE VISION INCORPORATED
To: RANBAXY, INC.
Reel/Frame 036584/0229 →
RELEASE OF SECURITY INTEREST Recorded Sep 16, 2015
From: QLT INC.
To: INSITE VISION, INC.
Reel/Frame 036578/0154 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jun 11, 2015
From: QLT INC.
To: INSITE VISION INCORPORATED
Reel/Frame 035889/0478 →
SECURITY INTEREST Recorded Oct 13, 2014
From: INSITE VISION INCORPORATED
To: U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 033975/0433 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2009
From: BOWMAN, LYLE M.; HOSSEINI, KAMRAN
To: INSITE VISION INCORPORATED
Reel/Frame 022518/0784 →